JTO Clinical and Research Reports (Apr 2024)

Osimertinib Plasma Trough Concentration in Relation to Brain Metastases Development in Patients With Advanced EGFR-Mutated NSCLC

  • Judith L. Gulikers, MSc,
  • G.D. Marijn Veerman, MD, PhD,
  • Merel Jebbink, MD, PhD,
  • Paul D. Kruithof, PharmD,
  • Christi M.J. Steendam, MD, PhD,
  • René J. Boosman, PhD,
  • Ron H.J. Mathijssen, MD, PhD,
  • Vivianne C.G. Tjan-Heijnen, MD, PhD,
  • Johanna H.M. Driessen, PhD,
  • Safiye Dursun, MD,
  • Egbert F. Smit, MD, PhD,
  • Anne-Marie C. Dingemans, MD, PhD,
  • Robin M.J.M. van Geel, PharmD, PhD,
  • Sander Croes, PharmD, PhD,
  • Lizza E.L. Hendriks, MD, PhD

Journal volume & issue
Vol. 5, no. 4
p. 100656

Abstract

Read online

Introduction: Brain metastases (BM) are common in patients with advanced EGFR-mutated (EGFRm+) NSCLC. Despite good BM-related outcomes of osimertinib, several patients still experience intracranial progression. A possible explanation is pharmacologic failure due to low plasma trough levels (Cmin,SS) and consequently limited intracranial osimertinib exposure. We investigated the relation between osimertinib Cmin,SS and BM development or progression. Methods: A prospective multicenter cohort study, including patients receiving osimertinib for advanced EGFRm+ NSCLC. At osimertinib start, patients were allocated to the BM or no or unknown BM cohort and were further divided into subgroups based on osimertinib Cmin,SS (low, middle, and high exposure). Cumulative incidence of BM progression or development and overall survival were determined for each group. Results: A total of 173 patients were included, with 49 (28.3%) had baseline BM. Of these patients, 36.7% experienced BM progression, of which 16.7% in the low (270.7 ng/mL) Cmin,SS subgroups. After 12 months, the cumulative incidence of BM progression for the BM cohort was 20% (95% confidence interval [CI] 2.6–49.0), 31% (95% CI:10.6–53.9), and 31% (95% CI:10.8–54.5) per Cmin,SS subgroup, respectively. After 20 months, this was 20% (95% CI:2.6–49.0), 52% (95% CI:23.8–74.2), and 57% (95% CI:24.9–79.7), respectively. For the no or unknown BM cohort, 4.0% developed BM without differences within Cmin,SS subgroups. Conclusions: No relation was found between osimertinib Cmin,SS and BM development or progression in patients with advanced EGFRm+ NSCLC. This suggests that systemic osimertinib exposure is not a surrogate marker for BM development or progression.

Keywords